Compare GSUN & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GSUN | GNPX |
|---|---|---|
| Founded | 1997 | 2009 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7M | 2.9M |
| IPO Year | 2020 | 2017 |
| Metric | GSUN | GNPX |
|---|---|---|
| Price | $0.23 | $3.35 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 5.2M | 82.1K |
| Earning Date | 02-13-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.17 | $0.16 |
| 52 Week High | $3.31 | $12.97 |
| Indicator | GSUN | GNPX |
|---|---|---|
| Relative Strength Index (RSI) | 41.29 | 38.51 |
| Support Level | $0.17 | $1.88 |
| Resistance Level | $0.55 | $3.62 |
| Average True Range (ATR) | 0.07 | 0.19 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 9.78 | 1.30 |
Golden Sun Technology Group Ltd operates two principal lines of business: tutorial services and e-commerce services. The company's e-commerce operations currently consist of data analytics-driven marketing and social media promotional services for small and medium-sized businesses on short video platforms based in China. The company's education centers offer two main programs, comprising of foreign language tutorial programs in less commonly taught languages, including, among other things, Spanish and Japanese, provided to individual students as well as to companies and other organizations; and Gaokao repeater tutorial programs, provided to individual students.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).